Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · IEX Real-Time Price · USD
3.200
+0.140 (4.58%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for AQST stock have an average target of 8.57, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 167.81% from the current stock price of 3.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AQST stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 3 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $9 | Buy | Reiterates | $9 | +181.25% | Jun 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +181.25% | Jun 5, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $8 | Buy | Initiates | $8 | +150.00% | May 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +181.25% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +181.25% | Apr 30, 2024 |
Financial Forecast
Revenue This Year
50.79M
from 50.58M
Increased by 0.41%
Revenue Next Year
59.73M
from 50.79M
Increased by 17.61%
EPS This Year
-0.55
from -0.13
EPS Next Year
-0.46
from -0.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 54.7M | 80.9M | 92.7M | 157.5M | 225.1M |
| Avg | 50.8M | 59.7M | 74.9M | 140.4M | 202.5M |
| Low | 46.3M | 48.8M | 44.6M | 124.3M | 170.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.1% | 59.2% | 55.2% | 110.3% | 60.3% |
| Avg | 0.4% | 17.6% | 25.4% | 87.5% | 44.2% |
| Low | -8.6% | -3.9% | -25.4% | 65.9% | 21.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.48 | -0.42 | -0.24 | -0.05 | 0.28 |
| Avg | -0.55 | -0.46 | -0.30 | -0.08 | 0.28 |
| Low | -0.61 | -0.55 | -0.34 | -0.11 | 0.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.